TipHub

294.15

-17.52 -5.62%

As of 28 Jul 2026 · delayed

NSE Listed · Healthcare

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-01
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

Suven Life Sciences Ltd. (SUVEN)

Volume: 11,03,601Avg Vol 1W: 7,79,364Avg Vol 1M: 18,37,94052W Range:124.11371
Market Cap₹8,312 Cr
Current Price₹294.15
Previous Close₹311.67
High / Low (52w)₹371 / ₹124.11
Volume11,03,601
Avg Vol (1W)7,79,364
Avg Vol (1M)18,37,940
Stock P/E
Book Value₹29.74
Dividend Yield0%
ROE-46.73%
ROA-44.27%
Revenue (TTM)
Revenue Growth-43.08%
Profit Margin-3,881.32%
Total Debt₹0 Cr
Shares Outstanding28 Cr
Face Value₹1
EPS (TTM)₹0
P/B9.89
Debt / Equity0
50 DMA₹290.02
200 DMA₹201.23
Day change-5.62%
SurveillanceLT-ASM · ASM 1
Price Chart
294.15 4.99% · 1Y
3601271.7Cr
2025-07-29
2026-07-28

20-day avg volume: 18.4L shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 46% YoY.
  • Company is loss-making at the latest annual result.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹1 Cr₹3 Cr₹2 Cr₹1 Cr₹2 Cr₹1 Cr₹3 Cr₹2 Cr
EBITDA₹-28 Cr₹-50 Cr₹-39 Cr₹-44 Cr₹-52 Cr₹-77 Cr₹-102 Cr₹-45 Cr
Net Profit₹-28 Cr₹-50 Cr₹-39 Cr₹-44 Cr₹-52 Cr₹-77 Cr₹-102 Cr₹-46 Cr
EPS
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹3 Cr₹2 Cr₹18 Cr₹1 Cr₹2 Cr₹1 Cr₹3 Cr₹2 Cr
EBITDA₹-11 Cr₹-13 Cr₹-161 Cr₹-15 Cr₹-15 Cr₹-15 Cr₹-13 Cr₹-11 Cr
Net Profit₹-11 Cr₹-13 Cr₹-161 Cr₹-15 Cr₹-15 Cr₹-15 Cr₹-13 Cr₹-11 Cr
EPS-7.37
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹919 Cr₹303 Cr₹182 Cr₹128 Cr₹108 Cr₹389 Cr₹285 Cr₹135 Cr
Total Liabilities₹152 Cr₹64 Cr₹39 Cr₹20 Cr₹12 Cr₹14 Cr₹15 Cr₹25 Cr
Equity₹767 Cr₹239 Cr₹143 Cr₹108 Cr₹96 Cr₹375 Cr₹270 Cr₹110 Cr
Total Debt
Cash Flow
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹113 Cr₹-38 Cr₹-132 Cr₹-95 Cr₹-127 Cr₹-115 Cr₹-122 Cr₹-155 Cr
Investing₹-1 Cr₹37 Cr₹146 Cr₹56 Cr₹-22 Cr₹-248 Cr₹94 Cr₹155 Cr
Financing₹-52 Cr₹5 Cr₹3 Cr₹35 Cr₹146 Cr₹396 Cr₹-1 Cr₹-1 Cr
Free Cash Flow₹113 Cr₹-38 Cr₹-132 Cr₹-95 Cr₹-127 Cr₹-115 Cr₹-122 Cr₹-155 Cr
Shareholding
Promoter 65.47% Institutions 3.21% Public 31.32%
Efficiency & Working Capital
ROCE-45.4%
Interest Coverage-944.6
Dividend Payout
Debtor Days73 d
Inventory Days13 d
Payable Days287 d
Cash Conversion Cycle-200 d
Working Capital Days86 d
Shareholding Details

As of 2026-08-31

Promoter65.5%
FII0.5%
DII2.7%
Institutions3.2%
Public31.3%
Promoter Pledge0%
No. of Shareholders66,647
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2024Dec 2024Mar 2025Jun 2025Jul 2025Jul 2025Sept 2025Dec 2025Mar 2026Jun 2026Jul 2026Aug 2026
Promoters70.3%70.3%70.3%70.3%67.4%67.4%67.4%67.4%70.2%70.1%65.5%65.5%
FIIs0.3%0.3%0.3%0.6%0.6%0.6%1.2%1.1%0.9%0.6%0.5%0.5%
DIIs1.1%1.1%0%0%3.4%3.4%3.4%3.4%4.6%2.9%2.7%2.7%
Public28.3%28.3%29.5%29.1%28.6%28.6%28.1%28.2%24.3%26.4%31.3%31.3%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders63,97563,53764,60366,15965,57465,57464,92164,38163,91566,79166,64766,647
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Jasti Property And Equity Holdings Private Limited (in Its Capacity As Sole Trustee Of Jasti FamilyShareholding of Promoter and Promoter Group64.9%18.35 Cr
3p India Equity Fund 1Public Shareholding1.2%33,58,209
Abakkus Diversified Alpha FundPublic Shareholding1%28,16,364
Sudharani JastiShareholding of Promoter and Promoter Group0.5%15,28,535
Kalyani JastiShareholding of Promoter and Promoter Group0%1,000
Sirisha JastiShareholding of Promoter and Promoter Group0%1,000
Madhavi JastiShareholding of Promoter and Promoter Group0%1,000
Venkateswarlu JastiShareholding of Promoter and Promoter Group0%2,201
Board of Directors
NameDesignationYear
Venkateswarlu JastiChairman / Executive Director / M D / Promoter2025
Sudha Rani JastiWTD & Executive Director2025
Seyed E HasnainNon Executive Director2025
Santanu MukherjeeIndependent Non Exe. Director2025
J A S PadmajaIndependent Non Exe. Director2025
Vajja Sambasiva RaoIndependent Non Exe. Director2025
Sangeetha Laxmi KandariCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Manufacturing (CRAMS)₹614 Cr92.5%
Services (DDDSS)₹50 Cr7.5%
Research and Development₹0 Cr0%
Segments — Geography
RegionRevenueShare
INDIA₹5 Cr71.1%
U S A₹0 Cr0.9%
EUROPE₹0 Cr5.2%
OTHERS₹2 Cr22.7%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹1302222
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20251140010115
20251140000114
2025000101
Insider / Designated-Person Trades

1 recent disclosure(s)

Jasti Property and Equity Holdings Private Limited in its capacity as sole trustee of Jasti Family TrustAcquisition · 3,17,68,764
Substantial Acquisitions (SAST)

1 disclosure(s)

Transmission28/05/2024 · 15,25,535
Company Information
Incorporated1989
ChairmanVenkateswarlu Jasti
AuditorKarvy & Co
🌐 www.suven.com

📍 #8-2-334 SDE Serene Chambers, 6 th Floor Road No 5 Avenue 7, Hyderabad, Telangana, 500034

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search